Davunetide vs Vasopressin

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Davunetide (AL-108; NAP; NAPVSIPQ) is a synthetic octapeptide derived from activity-dependent neuroprotective protein (ADNP), initially identified as a neuroprotective sequence from ADNP and investigated in clinical trials as a candidate treatment for cognitive impairment associated with schizophrenia and tauopathies including progressive supranuclear palsy. Davunetide is proposed to stabilize microtubule dynamics by interacting with tubulin and preventing tau hyperphosphorylation-related cytoskeletal disruption, and preclinical models demonstrated neuroprotective and procognitive effects at nanomolar concentrations. Clinical investigation included Phase 2 trials examining cognitive outcomes and MRS neuroimaging biomarkers in schizophrenia patients, and a Phase 2/3 trial in progressive supranuclear palsy; results showed some neurochemical effects but no consistent meaningful cognitive improvement across clinical endpoints, and the PSP program did not meet its primary outcomes. Davunetide has no FDA approval and no approved indication in any jurisdiction; clinical development has been discontinued following negative trial outcomes, and while its preclinical neuroprotective profile remains scientifically interesting, the clinical evidence does not establish efficacy for cognitive enhancement or neuroprotection in any condition.

Neuropeptide binding V1aR (social behavior/memory, vasoconstriction), V1bR (ACTH/stress), V2R (antidiuretic); enhances hippocampal memory consolidation and social recognition

Vasopressin (arginine vasopressin, AVP) is an endogenous hypothalamic nonapeptide approved in pharmaceutical form for central diabetes insipidus and as a vasopressor in septic shock; it acts through V1a receptors in the vasculature and brain and V2 receptors in the renal collecting duct to regulate blood pressure, water balance, and stress responsiveness. In the central nervous system, vasopressin functions as a neuromodulator involved in social recognition, stress-related memory encoding, and hippocampal synaptic plasticity, with V1a receptor activation in the dentate gyrus facilitating neuronal excitability and long-term potentiation. Preclinical studies document vasopressin-mediated enhancement of LTP in hippocampal circuits, and human neuroimaging research has demonstrated differential effects of intranasal vasopressin on social and memory-related neural activity compared to placebo. Vasopressin is an FDA-approved prescription drug; its use via intranasal delivery for cognitive or behavioral applications is investigational, and clinical evidence for cognitive enhancement in healthy individuals is very limited. Vasopressin vs desmopressin: the selectivity tradeoff Vasopressin's clinical use is primarily in critical care — vasopressin 0.03–0.04 units/minute IV is a standard vasopressor in septic shock and vasodilatory shock refractory to catecholamines, acting through V1a receptors in vascular smooth muscle to increase systemic vascular resistance. For antidiuretic indications (diabetes insipidus, nocturia), desmopressin is used instead of vasopressin because desmopressin's V2-selective action avoids the vasoconstriction, hypertension, and cardiac effects that V1a receptor activation produces. The two compounds should not be used interchangeably for the same indication. Intranasal vasopressin for cognitive and social research: Research interest in intranasal vasopressin for cognitive and social function applications has produced a mixed literature. A well-cited 2019 study (Parker et al., PNAS) found intranasal vasopressin increased social communication in autistic children; a subsequent larger replication trial did not reproduce the finding. For memory enhancement in healthy adults, controlled studies have generally shown no consistent benefit from single-dose intranasal AVP, with vasopressin's cognitive effects mediated by complex V1a receptor signaling in the hippocampus and amygdala that appears state-dependent (most evident in stress contexts). The compound remains a research tool for neuroendocrinology rather than a validated cognitive enhancer, and exogenous intranasal vasopressin is not commercially available in Western markets for this use.